Analyst Price Target is GBX 51
▲ +9.63% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Assura in the last 3 months. The average price target is GBX 51, with a high forecast of GBX 51 and a low forecast of GBX 51. The average price target represents a 9.63% upside from the last price of GBX 46.52.
Current Consensus is
Moderate Buy
The current consensus among 2 polled investment analysts is to moderate buy stock in Assura. This rating has held steady since June 2024, when it changed from a Buy consensus rating.
Assura plc is a specialist healthcare property investor and developer. We enable better health outcomes through our portfolio of more than 600 healthcare buildings across the UK and Ireland, from which over six million patients are served.
We BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).
Assura plc achieved B Corp certification in July 2024 - the first FTSE 250 business to do so.
Read More